Trial Profile

PHASE 1/2A DOSE ESCALATION AND EXPANSION STUDY EVALUATING SAFETY, TOLERABILITY, PHARMACOKINETIC, PHARMACODYNAMICS AND ANTI-TUMOR ACTIVITY OF PF-06873600 AS A SINGLE AGENT AND IN COMBINATION WITH ENDOCRINE THERAPY

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 06 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ebvaciclib (Primary) ; Fulvestrant; Hormone modulators; Letrozole
Indications Advanced breast cancer; Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Triple negative breast cancer
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors Pfizer

04 Feb 2025 Status changed from active, no longer recruiting to discontinued.
02 Mar 2023 Planned End Date changed from 5 Apr 2023 to 28 Nov 2024.
04 Oct 2022 Planned End Date changed from 23 Jan 2024 to 5 Apr 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com